Buy American panel discussion: How will this month's Executive Order impact drug and device companies, and what should you do about it?

On August 6, 2020, U.S. President Donald Trump issued his much-anticipated "Buy American" Executive Order (EO), aimed at shoring up domestic manufacture of "essential medicines", "medical...

Virtual health: What's on the horizon for telehealth and remote monitoring?

As the world responds to the COVID-19 pandemic, physicians and patients are increasingly turning to virtual health solutions, including telehealth and remote monitoring, as a central facet...

How landmark OTC drug reform legislation will affect your business

A team of our lawyers who counsel on Over-the-Counter (OTC) drug regulation will discuss the long-awaited OTC drug monograph reform that was part of the Coronavirus Aid, Relief, and...

How COVID-19 is changing the clinical trials landscape

Among the numerous repercussions of the COVID-19 pandemic, life sciences companies and academic medical centers are now faced with significant disruptions and threats to their clinical...

Introduction to Drug, Biologics, and Biosimilars Law and Regulation

Scott Kaplan presented the segment titled "Regulation of Manufacturing" at the Food and Drug Law Institute's Introduction to Drug, Biologics, and Biosimilars Law and Regulation course.

The impact of Brexit on the pharmaceutical and medical device industries

Our European Life Sciences Regulatory team has been examining the potential consequences of Brexit for the pharmaceutical and medical device industries since before the results of the...

Going Global 2018

Cross-practice, multi-track seminar on advanced trademark issues, global M&A transactions, global patent updates for technology companies, energy investments, and recent...

Life Sciences BREXIT Countdown

We have been examining the potential consequences of BREXIT for the pharmaceutical and medical device industries since before the results of the referendum were known. We are working with...

Loading data